<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00407186</url>
  </required_header>
  <id_info>
    <org_study_id>CRITICS</org_study_id>
    <nct_id>NCT00407186</nct_id>
  </id_info>
  <brief_title>Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer (CRITICS)</brief_title>
  <official_title>A Multicenter Randomized Phase III Trial of Neo-adjuvant Chemotherapy Followed by Surgery and Chemotherapy or by Surgery and Chemoradiotherapy in Resectable Gastric Cancer (CRITICS Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dutch Colorectal Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dutch Colorectal Cancer Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of combined chemotherapy and&#xD;
      radiotherapy (in comparison to chemotherapy alone) as adjuvant treatment after surgery for&#xD;
      gastric cancer. Prior to surgery all patients will receive neo-adjuvant chemotherapy as well.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The mainstay of curative treatment of gastric cancer is radical surgical dissection. Because&#xD;
      most patients in the Western world present with advanced stages long term survival is found&#xD;
      in about 25%, with local recurrences as part of treatment failure in up to 80% of cases.&#xD;
      Studies examining the role of more extended lymph node dissections (D1 vs. D2), adjuvant&#xD;
      radiotherapy or adjuvant chemotherapy did not result in a clinical relevant improvement of&#xD;
      survival. In 2001 results of a South West Oncology group (SWOG) trial that randomized between&#xD;
      surgery and surgery with chemoradiotherapy were published. This trial, that was hampered by&#xD;
      suboptimal surgery (less than D1 in majority of patients) and radiotherapy (2D radiotherapy;&#xD;
      35% protocol deviations) showed an absolute increase in median survival of 9 months. More&#xD;
      recently results of the MAGIC study, which randomized between surgery and surgery plus 6&#xD;
      perioperative courses of ECF chemotherapy, were presented. This regimen resulted in an&#xD;
      absolute 5-year survival benefit of 13% and in a 10% higher resectability rate.&#xD;
&#xD;
      This phase III prospectively randomized study investigates whether chemoradiotherapy (45 Gy&#xD;
      in 5 weeks with daily cisplatin and capecitabine) after preoperative chemotherapy (3x ECC&#xD;
      (epirubicin, cisplatin, capecitabine)) and adequate (D1+) surgery leads to improved survival&#xD;
      in comparison with postoperative chemotherapy (3x ECC). Furthermore, toxicity of both&#xD;
      treatment regimens will be explored.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 11, 2007</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>study duration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>health-related quality of life</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">788</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>1chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 weeksadjuvant treatment; radiotherapy and concomitant chemotherapy with cisplatin and capecitabine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 adjuvant courses epirubicin, cisplatin, capecitabine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin+capecitabine</intervention_name>
    <description>cisplatin 20 mg/m2 (i.v., q 1 w, 5 weeks), capecitabine 575 mg/m2 (b.i.d., oral, on radiotherapy days.</description>
    <arm_group_label>1chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>45 Gy in 25 fracions (5 days/week)</description>
    <arm_group_label>1chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin+cisplatin+capecitabine</intervention_name>
    <description>3 courses q 3 w: epirubicin 50 mg/m2 (i.v., day 1), cisplatin 60 mg/m2 (i.v., day 1), capecitabine 1000 mg/m2 (b.i.d., oral, day 1-14)</description>
    <arm_group_label>2chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ib-IVa (no distant metastases) gastric cancer (histologically proven); tumor bulk in&#xD;
             the stomach&#xD;
&#xD;
          -  WHO &lt; 2&#xD;
&#xD;
          -  Age â‰¥18 yrs&#xD;
&#xD;
          -  Operable gastric cancer&#xD;
&#xD;
          -  No prior abdominal radiotherapy or chemotherapy&#xD;
&#xD;
          -  Tumornegative laparoscopy when CT suggests peritoneal carcinomatosis&#xD;
&#xD;
          -  Start treatment within 10 working days after registration&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  T1N0 disease (endoscopic ultrasound)&#xD;
&#xD;
          -  Distant metastases&#xD;
&#xD;
          -  Inoperable patients; due to technical surgery-related factors or general condition&#xD;
&#xD;
          -  Previous malignancy, except adequately treated non-melanoma skin cancer or in-situ&#xD;
             cancer of the cervix uteri.&#xD;
&#xD;
          -  Solitary functioning kidney that will be within the radiation field&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to study treatment start, or lack of complete&#xD;
             recovery from the effects of major surgery&#xD;
&#xD;
          -  Uncontrolled (bacterial) infections&#xD;
&#xD;
          -  Significant cardiac disorders&#xD;
&#xD;
          -  Continuous use of immunosuppressive agents&#xD;
&#xD;
          -  Concurrent use of the antiviral agent sorivudine or chemically related analogues&#xD;
&#xD;
          -  Hearing loss &gt; CTC grade 1&#xD;
&#xD;
          -  Neurotoxicity &gt; CTC grade 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcel Verheij, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nederlands Kanker Insituut/Antoni van Leeuwenhoek Ziekenhuis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nederlands Kanker Instituut/Antoni van Leeuwenhoek Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.dccg.nl</url>
    <description>Dutch Colorectal Cancer Group</description>
  </link>
  <link>
    <url>http://www.nki.nl</url>
    <description>Nederlands Kanker Instituut/Antoni van Leeuwenhoek Ziekenhuis (Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital)</description>
  </link>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>December 1, 2006</study_first_submitted>
  <study_first_submitted_qc>December 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2006</study_first_posted>
  <last_update_submitted>October 9, 2017</last_update_submitted>
  <last_update_submitted_qc>October 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRITICS</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>surgery</keyword>
  <keyword>adjuvant</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>chemoradiotherapy</keyword>
  <keyword>capecitabine</keyword>
  <keyword>cisplatin</keyword>
  <keyword>epirubicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

